Tuesday, August 19, 2014
Premium readers over at PropThink.com are already up 15% since our buy recommendation was issued on Amicus Therapeutics [FOLD] on August 7 at $4.00 per share.
Though the investment premise remains intact, investors might want to either lock in existing short-term gains, or buy September 5 calls as downside insurance against any near-term clinical surprises.
Albeit the investment thesis is focused on monotherapy use of its proprietary, pharmacological chaperone migalastat in Fabry Disease, there are value-creating assets that should become more visible in late 2015. In the treatment of Pompe disease (a glycogen storage disorder caused by deficiency of an enzyme called acid α-glucosidase), Amicus is looking to leverage its proprietary Chaperone-Advanced Replacement Therapy platform to improve currently marketed ERTs through co-administration of a pharmacological chaperone prior to ERT infusion, and/ or to develop next-generation ERTs that consist of a proprietary lysosomal enzyme therapy co-formulated with a pharmacological chaperone.
Those investors looking for additional insight into our thoughts on FOLD and visible catalysts, such as Study 012, might consider opening their wallets and purchasing a subscription to PropThink.com.
Read more at PropThink: COMING UP: MAKE OR BREAK FOR AMICUS’ PHARMACOLOGICAL CHAPERONE TECHNOLOGY
Editor David J Phillips no longer holds a financial interest in any stocks mentioned in this article. The 10Q Detective has a Full Disclosure Policy.
Tuesday, August 12, 2014
Ignore OncoGeneX’s (OGXI-$3.15) reported second-quarter 2014 loss of 47 cents per share. Investors, instead, should focus on existing positives and visible price catalysts coming up in the next 12-months, including:
- Management: "Based on our current expectations, we believe our capital resources will be sufficient to fund our currently planned operations into the third quarter of 2016. " Company recently completed a $22.4 million cash raise.
- The SYNERGY Trial: Results of the SYNERGY trial will be presented at the European Society for Medical Oncology (ESMO) 2014 Congress (September) in Madrid.
- Management addressed previous unknown raised in a recent PropThink article on ENSPIRIT trial too: "We expect to evaluate both progression-free survival, or PFS (PFS rate at 14 weeks in 170 patients), and overall survival, or OS (OS at 100 events), during the first interim futility analysis"; The first of two analyses is expected to be conducted in 2014.
- The Borealis-2 Trial (investigator-sponsored, randomized Phase 2 trial evaluating apatorsen in combination with docetaxel treatment compared to docetaxel treatment alone in patients with advanced or metastatic bladder cancer who have disease progression following first-line platinum-based chemotherapy) could be a big win, as more than 50% of patients with urothelial cancer of bladder discontinue FIRST-LINE treatment with cisplatin either due to non-responsiveness and/ or toxicity.
Continue reading at PropThink: NO ONE”S EXCITED ABOUT ONCOGENEX, WHICH MAKES IT WORTH A LOOK
Editor David J Phillips holds a financial interest in OncoGenex common stock. The 10Q Detective has a Full Disclosure Policy.